Looking at TScan Therapeutics, Inc.'s ( NASDAQ:TCRX ) insider transactions over the last year, we can see that ...

TScan Therapeutics Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company with a market capitalization of $139.57 million, is poised at a critical juncture in its development of innovative ...

The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...

TScan Therapeutics (TCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating ...

TScan Therapeutics (TCRX) has entered into a term loan facility with Silicon Valley Bank, a division of First Citizens Bank, for up to $52.5 million. The first tranche of $32.5 million ...

TScan Therapeutics Price Performance TCRX stock opened at $3.07 on Friday. The business’s fifty day moving average price is $4.12 and its 200 day moving average price is $5.29. TScan ...

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ...

The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...